Long-Term Interferon Maintenance Therapy Improves Survival in Patients with HCV-Related Hepatocellular Carcinoma after Curative Radiofrequency Ablation
- 1 December 2007
- journal article
- Published by S. Karger AG in Oncology
- Vol. 72 (Suppl. 1), 132-138
- https://doi.org/10.1159/000111719
Abstract
Objective: To assess whether low-dose, long-term maintenance interferon (IFN) therapy inhibits recurrence after complete ablation of hepatocellular carcinoma (HCC) and improves patient survival. Methods and Patients: From June 1999 through May 2006, a total of 127 HCC cases that met the requirements of both tumor diameter 3 cm or less, and number of tumors three or fewer, were curatively treated by radiofrequency ablation therapy (RFA). Among them, 43 patients received three million IU of IFN-α2b twice per week or pegylated IFN-α2a 90 µg once per week or once per 2 weeks without discontinuation (IFN maintenance group). The remaining 84 patients, whose sex, age, and platelet counts were randomly matched to those of the IFN maintenance group, did not receive IFN treatment (control group). Results: Cumulative first, second, and third recurrence rates were significantly reduced in the IFN maintenance group compared with the control group by Kaplan-Meier estimate. The 5-year survival rate was 66% for the control group and 83% for the IFN maintenance group (p = 0.004). Multivariate analysis using the Cox proportional hazards model identified IFN maintenance therapy as an independent risk factor for survival, and the risk ratio was 0.21 (95% CI: 0.05–0.73). In conclusion, low-dose, long-term maintenance IFN therapy after curative RFA therapy of HCC significantly inhibits recurrence, and consequently improves patient survival.Keywords
This publication has 23 references indexed in Scilit:
- Low-Dose, Long-Term, Intermittent Interferon-alpha-2b Therapy after Radical Treatment by Radiofrequency Ablation Delays Clinical Recurrence in Patients with Hepatitis C Virus-Related Hepatocellular CarcinomaIntervirology, 2005
- Interferon-αCon1 suppresses proliferation of liver cancer cell lines in vitro and in vivoJournal of Hepatology, 2004
- Local ablation therapy for hepatocellular carcinoma: current status and future perspectivesThe Esophagus, 2004
- Prospective randomized controlled study of interferon‐alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumorsCancer, 2004
- Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis CHepatology, 2003
- Mechanism of Interferon Alpha on Inhibition of Metastasis and Angiogenesis of Hepatocellular Carcinoma After Curative Resection in Nude MiceJournal of Gastrointestinal Surgery, 2003
- Hepatocellular CarcinomaJournal of Clinical Gastroenterology, 2002
- Influence of Previous Interferon Therapy on Recurrence after Resection of Hepatitis C Virus‐related Hepatocellular CarcinomaJapanese Journal of Cancer Research, 2001
- Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell linesHepatology, 1999